Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

On Friday, Boston Scientific Corporation (BSX) stock saw a modest uptick, ending the day at $88.25 which represents a slight increase of $1.37 or 1.58% from the prior close of $86.88. The stock opened ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.